Estrella Immunopharma (ESLA) Receivables - Net (2023)
Estrella Immunopharma (ESLA) posted quarterly Receivables - Net of $273066.0 for Q3 2023, little changed quarter-over-quarter from $273066.0 in Q2 2023.
Estrella Immunopharma (ESLA) Receivables - Net (2023) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Receivables - Net for 1 consecutive years, with $273066.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Receivables - Net changed N/A year-over-year to $273066.0; the TTM figure through Sep 2023 stood at $273066.0 (changed N/A YoY), while the FY2023 annual figure was $273066.0, changed N/A from the prior year.
- Receivables - Net steadied at $273066.0 in Q3 2023 per ESLA's latest filing, from $273066.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $273066.0 in Q2 2023 and bottomed at $273066.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 273,066.00 |
| Sep 30, 2023 | 273,066.00 |
| Jun 30, 2023 | 273,066.00 |
| Jun 30, 2023 | 273,066.00 |